Nuveen’s Palvella Therapeutics PVLA Stock Holding History

Nuveen’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.6M	Buy	20,834 +1,258	+6%	+$131K	﹤0.01%	2170
2025 Q4	$2.05M	Buy	19,576 +6,871	+54%	+$586K	﹤0.01%	2282
2025 Q3	$796K	Buy	12,705 +3,800	+43%	+$169K	﹤0.01%	2726
2025 Q2	$201K	Buy	+8,905	New	+$209K	﹤0.01%	3159
2021 Q2	–	Sell	-2,084	Closed	-$428K	–	3557
2021 Q1	$428K	Buy	2,084 +15	+0.7%	+$3.28K	﹤0.01%	3122
2020 Q4	$414K	Buy	2,069 +22	+1%	+$4.58K	﹤0.01%	3082
2020 Q3	$339K	Hold	2,047	–	–	﹤0.01%	3055
2020 Q2	$508K	Sell	2,047 -114	-5%	-$26.7K	﹤0.01%	2889
2020 Q1	$394K	Sell	2,161 -2,855	-57%	-$719K	﹤0.01%	2854
2019 Q4	$1.45M	Buy	5,016 +552	+12%	+$153K	﹤0.01%	2549
2019 Q3	$1.22M	Sell	4,464 -3,544	-44%	-$1.37M	﹤0.01%	2614
2019 Q2	$3.01M	Buy	+8,008	New	+$2.39M	﹤0.01%	2246

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen's PVLA Position: Q1 2026 in Review

Nuveen increased its Palvella Therapeutics (PVLA) stake by 6.4% in Q1 2026, buying an estimated $131K and bringing the position to 20,834 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2170.

Nuveen first reported a position in PVLA in Q2 2019 and has held it in 12 quarters since. The position peaked at $3.01M in Q2 2019. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Nuveen held 20,834 shares of Palvella Therapeutics worth $2.6M as of Q1 2026.
Nuveen bought 1,258 Palvella Therapeutics shares in Q1 2026, an estimated $131K.
Palvella Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2170 holding.
Nuveen first reported a position in Palvella Therapeutics in Q2 2019 and has held it in 12 quarters since.
Nuveen's Palvella Therapeutics position peaked at $3.01M in Q2 2019.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.